Anemia (Renal)
DC 7700Medical Rationale
The kidneys produce 90% of circulating erythropoietin (EPO), the glycoprotein hormone that stimulates red blood cell production in the bone marrow. As CKD progresses and functional renal parenchyma is lost, EPO production declines proportionally, resulting in normocytic normochromic anemia of chronic kidney disease. This EPO-deficient anemia typically becomes clinically significant at GFR <45 mL/min (CKD Stage 3b) and is nearly universal by GFR <15 mL/min (CKD Stage 5). Additionally, uremic toxins suppress erythropoiesis directly, shorten red blood cell lifespan from the normal 120 days to 60-90 days, and impair iron absorption and utilization. CKD-related anemia produces fatigue, exercise intolerance, cognitive impairment, and cardiovascular strain from compensatory increased cardiac output.
Key Studies
Babitt JL & Lin HY (2012) J Am Soc Nephrol (mechanisms of anemia in CKD); Stauffer ME & Fan T (2014) PLoS One (prevalence of anemia in CKD — systematic review).
Filing Tips
Complete blood count showing normocytic normochromic anemia. Serum EPO level (low or inappropriately normal for the degree of anemia). Renal function tests documenting CKD stage. Iron studies to rule out concurrent iron deficiency. Nephrology or hematology nexus letter addressing EPO deficiency as the mechanism. Document functional impairment from anemia (fatigue, exercise intolerance). Consider under DC 7700 (anemia, hypochromic-microcytic and iron deficiency — used broadly for anemias) or consider filing under the renal disability rating if anemia symptoms are addressed there.